nipah
viru
niv
new
zoonot
paramyxoviru
emerg
classifi
genu
henipaviru
along
close
relat
hendra
viru
hev
niv
highli
pathogen
sever
vertebr
speci
includ
human
lack
avail
vaccin
specif
treatment
restrict
biosafeti
level
contain
serum
neutral
test
develop
measur
niv
neutral
antibodi
condit
use
recombin
vesicular
stomat
viru
vsv
express
green
fluoresc
protein
gfp
bear
f
g
protein
niv
vsvnivgfp
neutral
titer
obtain
count
gfpexpress
cell
measur
fluoresc
perform
new
assay
compar
convent
test
use
live
niv
panel
sera
sever
mammalian
speci
includ
sera
niv
outbreak
experiment
infect
well
hevspecif
sera
result
obtain
vsvnivgfp
base
test
correl
obtain
use
live
niv
use
reduct
vsvnivgfp
infect
cell
cutoff
neutral
new
assay
demonstr
potenti
effect
tool
detect
niv
neutral
antibodi
contain
greater
speed
sensit
safeti
compar
convent
niv
serum
neutral
test
nipah
viru
niv
highli
pathogen
paramyxoviru
emerg
causal
agent
respiratori
diseas
pig
acut
febril
enceph
human
work
pig
industri
malaysia
singapor
chua
et
al
niv
classifi
new
genu
henipaviru
base
uniqu
genet
characterist
distinct
paramyxovirus
eaton
et
al
eaton
et
al
togeth
hendra
viru
hev
caus
repeat
incid
sever
respiratori
neurolog
diseas
among
hors
human
australia
sinc
bishop
broder
murray
et
al
natur
niv
infect
also
confirm
dog
cat
hors
niv
outbreak
occur
bangladesh
india
almost
everi
year
sinc
bishop
broder
chadha
et
al
harcourt
et
al
hsu
et
al
henipaviru
reservoir
appear
sever
speci
fruit
bat
primarili
genu
pteropu
niv
outbreak
malay
peninsula
human
speci
presum
infect
intermedi
speci
pig
eaton
et
al
hand
niv
outbreak
bangladesh
involv
anim
fruit
bat
confirm
indic
direct
transmiss
bat
human
hsu
et
al
lubi
et
al
humantohuman
transmiss
also
suggest
base
epidemiolog
studi
conduct
bangladesh
gurley
et
al
b
presenc
antibodi
niv
nivlik
virus
fruit
bat
report
thailand
wacharapluesade
et
al
cambodia
olson
et
al
reyn
et
al
indonesia
sendow
et
al
madagascar
lehl
et
al
ghana
hayman
et
al
china
li
et
al
safe
rapid
serolog
diagnosi
niv
infect
sever
enzymelink
immunosorb
assay
elisa
develop
although
specif
elisa
fairli
high
still
yield
fals
posit
result
mean
confirmatori
diagnosi
requir
anim
suspect
infect
niv
elisa
serum
neutral
test
detect
neutral
antibodi
viral
fusion
f
andor
attach
g
glycoprotein
regard
current
gold
standard
serolog
diagnosi
accept
refer
standard
world
organ
anim
health
oie
oie
although
crossreact
exist
niv
hev
serum
neutral
test
differenti
sera
test
virus
simultan
due
highli
pathogen
natur
niv
hev
absenc
therapeut
prophylact
measur
classifi
biosafeti
level
pathogen
serum
neutral
test
use
live
viru
must
conduct
condit
oie
safeti
concern
prompt
develop
system
detect
neutral
antibodi
niv
without
use
live
infecti
viru
one
promis
system
base
vesicular
stomat
viru
vsv
g
recombin
vsv
whose
g
gene
replac
green
fluoresc
protein
gfp
gene
lawson
et
al
takada
et
al
studi
serum
neutral
test
use
vsvbase
pseudotyp
viru
possess
nivf
g
develop
result
neutral
test
use
vsvnivgfp
found
well
correl
obtain
use
live
niv
use
reduct
vsvnivgfp
infect
cell
cutoff
neutral
assay
demonstr
potenti
rapid
sensit
method
standard
serum
neutral
test
use
liveniv
furthermor
vsvnivgfp
base
neutral
assay
could
carri
condit
elimin
use
infecti
niv
requir
contain
also
improv
safeti
vero
cell
maintain
eagl
minimum
essenti
medium
emem
includ
fetal
calf
serum
fc
niv
isol
human
brain
tissu
outbreak
malaysia
chua
et
al
propag
vero
cell
store
c
use
experi
use
liveniv
conduct
strict
biocontain
procedur
laboratori
australian
anim
health
laboratori
construct
express
plasmid
encod
nivf
g
gene
code
region
f
g
protein
amplifi
viral
cdna
f
gene
amplifi
randomli
prime
cdna
forward
primer
cgc
gga
tcc
tcg
aca
atg
gta
gtt
ata
ctt
revers
primer
ggt
tga
agc
ttc
aat
ctg
aat
aca
cta
tgt
first
clone
prseta
vector
invitrogen
carlsbad
ca
usa
follow
subclon
pcagg
vector
kind
gift
dr
j
miyazaki
osaka
univers
japan
niwa
et
al
cdna
g
gene
clone
vector
pcagg
describ
elsewher
patch
et
al
sera
variou
speci
use
studi
shown
tabl
rabbit
obtain
immun
plasmid
dna
nivfpcagg
nivgpcagg
see
briefli
rabbit
receiv
g
plasmid
dna
inject
total
eight
time
use
serum
neutral
test
studi
sera
screen
antibodi
elisa
use
inactiv
viral
antigen
describ
elsewher
gener
vsv
pseudotyp
nivfg
perform
accord
fukushi
et
al
sever
modif
nivfpcagg
nivgpcagg
dna
cotransfect
confluent
cell
use
fugen
hd
roch
basel
switzerland
accord
manufactur
instruct
cell
incub
c
co
incub
h
replac
medium
hr
posttransfect
follow
infect
vsv
g
kind
gift
dr
whitt
gtx
inc
tn
usa
multipl
infect
moi
h
cultur
supernat
contain
vsv
pseudotyp
nivfg
vsvnivgfp
collect
supernat
centrifug
remov
cell
debri
filter
pore
size
filter
store
c
serial
dilut
vsvnivgfp
fc
inocul
onto
vero
cell
monolay
seed
cultur
plate
h
incub
number
gfpposit
cell
well
determin
use
fluoresc
microscopi
titer
vsvnivgfp
defin
reciproc
highest
dilut
gave
rise
posit
fluoresc
express
infecti
unit
viru
stock
determin
contain
infecti
unitsml
serial
twofold
dilut
l
sera
mix
equal
volum
vsvnivgfp
supernat
contain
infecti
unit
pseudotyp
virus
incub
c
h
l
mixtur
inocul
onto
vero
cell
monolay
plate
triplic
cultur
incub
c
h
neutral
titer
determin
number
cell
emit
fluoresc
count
use
fluoresc
microscop
olympu
tokyo
japan
biozero
keyenc
osaka
japan
altern
fluoresc
intens
individu
well
measur
use
fluoroskan
ascent
luminomet
thermo
fisher
scientif
waltham
usa
condit
ms
integr
excit
emiss
nm
nm
respect
serial
twofold
dilut
test
sera
made
use
emem
without
fc
l
aliquot
serial
dilut
antibodi
mix
equal
volum
emem
contain
tcid
live
niv
incub
min
c
l
vero
cell
suspens
contain
cellsml
ad
mixtur
incub
c
co
incub
day
neutral
titer
express
reciproc
dilut
antibodi
complet
block
develop
cpe
test
whether
vsvnivgfp
could
use
place
live
viru
serum
neutral
test
niv
rabbit
sera
nivor
hevreact
sera
tabl
examin
abil
neutral
vsvnivgfp
studi
level
pseudotyp
viru
infect
determin
primarili
count
gfpexpress
cell
preincub
rabbit
sera
neutral
infect
vsvnivgfp
dosedepend
manner
fig
neutral
tabl
comparison
neutral
titer
vsvnivgfp
liveniv
base
assay
chua
et
al
observ
sera
naiv
rabbit
fig
altern
fluoresc
intens
individu
well
measur
use
plate
fluoromet
indic
vsvnivgfp
infect
although
latter
method
gave
nonspecif
fluoresc
sever
well
due
presenc
debri
result
obtain
method
correl
well
well
show
extraordinarili
high
fluoresc
intens
omit
data
shown
subsequ
serum
neutral
test
perform
use
sera
sever
speci
anim
tabl
vsvnivgfp
neutral
sera
variou
anim
includ
human
posit
nivspecif
elisa
except
one
serum
cat
fig
neutral
activ
observ
sera
neg
elisa
howev
naiv
sera
cat
fig
specif
vsvnivgfp
infect
vsvnivgfp
preincub
serial
dilut
rabbit
sera
nonimmun
sera
b
infect
vsvnivgfp
measur
count
gfpexpress
cell
number
gfpexpress
cell
absenc
sampl
serum
set
result
shown
mean
sd
least
three
independ
assay
fig
elisa
neg
show
vsvnivgfp
neutral
lower
dilut
like
due
low
level
nonspecif
inhibit
pseudotyp
viru
infect
sinc
elisa
neg
sera
anim
pig
particular
appear
show
slight
inhibit
vsvnivgfp
infect
lower
dilut
sera
examin
pig
sera
japan
niv
infect
detect
examin
presenc
nonspecif
inhibit
pseudotyp
viru
infect
confirm
whether
inhibit
relat
preexposur
pathogen
pig
includ
pig
group
confirm
antibodi
japanes
enceph
viru
jev
four
pig
group
b
jev
antibodyposit
shown
fig
sera
exhibit
vari
level
nonspecif
inhibit
dilut
less
sinc
sera
group
b
posit
show
slightli
higher
inhibit
vsvnivgfp
anoth
serum
neutral
test
conduct
use
sera
obtain
five
pig
previou
experi
infect
experiment
jev
william
et
al
interestingli
five
sera
show
inhibit
vsvnivgfp
infect
even
minimum
serum
dilut
fig
indic
nonspecif
inhibit
seen
pig
group
b
fig
attribut
exist
cutoff
valu
defin
posit
versu
neg
test
outcom
threshold
serum
concentr
analyz
determin
next
purpos
sera
obtain
japanes
field
pig
fig
thought
previou
exposur
niv
use
previou
report
serum
neutral
test
use
pseudotyp
virus
express
spike
glycoprotein
sever
acut
respiratori
syndrom
coronaviru
sarscov
fukushi
et
al
fukushi
et
al
reduct
infect
compar
noserum
control
use
cutoff
valu
defin
posit
neutral
outcom
studi
similar
approach
use
neutral
titer
defin
reciproc
highest
serum
dilut
result
least
reduct
vsvnivgfp
infect
analysi
data
present
fig
seroneg
pig
demonstr
nonspecif
inhibit
may
occur
serum
sampl
dilut
sampl
sera
greater
start
dilut
avoid
potenti
nonspecif
inhibit
allow
test
sampl
small
amount
sera
avail
test
dilut
sera
preliminari
screen
seroposit
anim
sera
test
shown
fig
would
correctli
character
either
posit
fig
reduct
curv
vsvnivgfp
infect
obtain
serum
neutral
test
sera
variou
speci
human
fruit
bat
b
hors
c
cat
nivexperimentallyinfect
pig
e
malaysian
field
pig
f
infect
vsvnivgfp
measur
count
number
gfpexpress
cell
describ
fig
neg
support
use
threshold
serum
concentr
determin
specif
neutral
high
confid
use
neutral
test
paramet
defin
neutral
titer
sera
determin
new
serum
neutral
test
vsvnivgfp
compar
obtain
convent
test
liveniv
tabl
sera
neutral
titer
use
vsvnivgfp
base
assay
significantli
higher
obtain
use
convent
neutral
test
employ
liveniv
appear
posit
correl
neutral
titer
obtain
method
within
respect
speci
antigen
case
rabbit
monospecif
antisera
howev
exact
correl
coeffici
could
obtain
sinc
neutral
titer
sever
sera
exceed
highest
dilut
use
studi
serum
neutral
test
liveniv
two
sera
malaysian
pig
no
show
cell
toxic
use
lowest
dilut
studi
serum
neutral
test
use
pseudotyp
virus
possess
nivfg
protein
vsvnivgfp
detect
niv
infect
develop
due
inabl
produc
infecti
progeni
viru
quantit
natur
pseudotyp
virus
would
provid
safe
diagnost
tool
conduct
serum
neutral
test
facilit
research
viru
entri
cell
tropism
one
pseudotyp
system
use
commonli
base
vesicular
stomat
viru
vsv
vsv
g
system
vsv
g
gene
replac
green
fluoresc
protein
gfp
gene
far
vsv
g
system
report
produc
sever
pseudotyp
virus
incorpor
envelop
glycoprotein
rna
virus
measl
viru
tatsuo
et
al
hantaviru
ogino
et
al
ebola
viru
takada
et
al
hepat
c
viru
matsuura
et
al
sever
acut
respiratori
syndrom
coronaviru
sarscov
fukushi
et
al
diagnost
neutral
test
use
sarscov
proteinsbear
pseudotyp
virus
report
sensit
convent
viru
neutral
test
use
live
sarscov
fukushi
et
al
recent
pseudotyp
virus
possess
nivfg
develop
examin
viru
entri
negret
et
al
howev
yet
examin
potenti
diagnost
applic
use
serum
neutral
test
studi
infect
vsvnivgfp
measur
count
number
gfpexpress
cell
measur
fluoresc
intens
use
plate
fluoromet
new
assay
signific
sever
level
afford
rapid
highthroughput
diagnosi
facilit
epidemiolog
monitor
outbreak
investig
surveil
conduct
condit
greater
level
safeti
substanti
cost
save
neutral
titer
sera
variou
speci
compar
method
convent
test
use
liveniv
although
seem
posit
correl
result
obtain
two
method
former
appear
far
sensit
latter
tabl
remark
high
sensit
like
due
inabl
vsvnivgfp
undergo
multicycl
replic
due
lack
g
gene
inde
neutral
vsvnivgfp
therefor
achiev
neutral
antibodi
inhibit
initi
bind
pseudotyp
virus
cell
wherea
case
serum
neutral
test
employ
liveniv
viru
success
enter
cell
replic
multipli
typic
greater
level
neutral
antibodi
requir
inhibit
viral
spread
often
result
appar
lower
neutral
titer
advantag
vsvnivgfp
system
abil
use
far
less
serum
henc
reduc
potenti
effect
cell
toxic
tabl
addit
data
also
demonstr
nivneutr
antibodi
detect
level
convent
neutral
test
could
detect
use
assay
system
exampl
cat
tabl
nonspecif
inhibit
pseudotyp
viru
infect
seen
particularli
pig
sera
studi
also
observ
previou
studi
fukushi
et
al
gener
field
sera
seem
problemat
exhibit
nonspecif
reactiv
serum
diagnosi
elisa
viru
neutral
test
sera
anim
infect
experiment
result
shown
fig
indic
nonspecif
inhibit
result
antibodi
one
possibl
nonspecif
reactiv
may
result
differ
nutrit
immunolog
condit
anim
degre
hemolysi
prepar
sampl
howev
set
appropri
threshold
serum
concentr
minim
influenc
nonspecif
activ
reliabl
diagnosi
achiev
fig
antisera
niv
hev
shown
crossneutr
make
imposs
defin
viral
etiolog
base
serum
neutral
test
use
singl
viru
niv
hev
differenti
better
two
viral
infect
develop
pseudotyp
virus
possess
hevfg
requir
howev
sinc
current
epidemiolog
inform
seem
indic
nonoverlap
geograph
distribut
niv
hev
vsvbase
assay
system
could
serv
use
tool
carri
seroepidemiolog
investig
either
viru
hevspecif
system
establish
conclus
serum
neutral
test
use
pseudotyp
viru
niv
possess
sever
advantag
convent
assay
use
live
viru
develop
assay
requir
use
live
viru
conduct
safe
condit
provid
new
diagnost
tool
help
facilit
studi
epidemiolog
niv
one
deploy
readili
countri
contain
laboratori
avail
